Advertisement


Alicia Latham, MD, MS, on Using ctDNA to Detect Endometrial Cancer

2025 ASCO Annual Meeting

Advertisement

Alicia Latham, MD, MS, of Memorial Sloan Kettering Cancer Center, discusses the feasibility of using Pap-derived ctDNA for the detection of sporadic and Lynch syndrome–associated endometrial cancer (Abstract 10503). 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The study is important because for the longest time women's only option if they had an increased risk for gynecologic cancer because of hereditary predisposition like BRCA or Lynch syndrome or some of these other hereditary susceptibilities was they were recommended to and still are recommended to undergo risk-reducing hysterectomy. So it's a major quality of life issue. Right now, the only possible screening option for women with Lynch syndrome for uterine cancer is endometrial biopsy. The NCCN recommends that women can consider this. But unfortunately we know that they don't really work very well in terms of detecting uterine cancer as a pure screening test. And they're also very invasive and uncomfortable and cause a lot of pain. The idea behind the study is to try to develop a new way to screen for uterine cancer by using cell-free DNA, which we all know as more of a blood-based test, but in actuality, you can extract cell-free DNA from multiple body fluids. And so what the study has done is we looked at 16 patients with known uterine cancer that were going in for surgical operation, collected both a blood test and a cervical sample and extracted cell-free DNA from both body fluids. And then we compared tumor mutations, we sequenced them, compared tumor mutations in the actual tumor cancers to those that were found in the blood and those that were found in the cervical mucus sampling. And we found in what we're calling Pap ctDNA that over 90% of our mutations were detected in these early-stage cancers. In fact, it was 93% in FIGO grade 1 uterine cancer. In comparison, the blood test only detected about one-quarter of these. So we have a lot of work to do. This is a small feasibility study. We're in the process of expanding this more. I'm working on looking at other tumor types such as ovarian, which I've already been asked about, and hopefully we’ll be able to have an option for women for screening for these cancers for which they have not had effective screening.

Related Videos

Asaf Maoz, MD, on Li-Fraumeni Syndrome: Multimodality Screening Program 

Asaf Maoz, MD, of Dana-Farber Cancer Institute/Mass General Brigham/Harvard Medical School, reviews the results of a prospective study of whole-body magnetic resonance imaging as part of cancer screening for individuals with Li-Fraumeni syndrome (Abstract 10501). 

Colorectal Cancer

Christopher M. Booth, MD, on a Structured Exercise Program for Patients With Colon Cancer

Christopher M. Booth, MD, of Queen’s University, reviews findings from the randomized phase III Canadian Cancer Trials Group (CCTG) CO.21 (CHALLENGE) trial, which evaluated the impact of a structured exercise program on disease-free survival in patients with stage III or high-risk stage II colon cancer (Abstract LBA3510). 

Lung Cancer

Martin Reck, MD, PhD, on Postsurgical MRD, Genomic Mutations, and Outcomes in Resectable NSCLC: AEGEAN Trial

Martin Reck, MD, PhD, of LungenClinic Grosshansdorf, Germany, discusses data from the phase III AEGEAN trial that studied perioperative durvalumab and neoadjuvant chemotherapy. Patients who were MRD-positive after surgery had significantly worse disease-free survival compared to MRD-negative patients. In addition, mutations in KEAP1 and KMT2C were associated with MRD positivity and reduced benefit from the regimen, identifying a small high-risk subgroup with poor prognosis (Abstract 8009). 

Genomics/Genetics

Angela R. Bradbury, MD, on Genetic Testing Approach in Patients With Metastatic Cancers

Angela R. Bradbury, MD, of the University of Pennsylvania, presents findings from the eREACH trial—a randomized study of an eHEALTH delivery alternative for cancer genetic testing for hereditary predisposition in patients with metastatic cancers (Abstract 10502).  

Prostate Cancer

Gerhardt Attard, MD, PhD, on a Novel Regimen for Metastatic Castration-Sensitive Prostate Cancer With HRR Alterations

Gerhardt Attard, MD, PhD, of the Cancer Institute, University College London, presents findings from the phase III AMPLITUDE trial, which looked at the combination of niraparib and abiraterone acetate plus prednisone for patients with metastatic castration-sensitive prostate cancer with alterations in homologous recombination repair (HRR) genes (Abstract LBA5006). 

Advertisement

Advertisement




Advertisement